Targeting of Prosurvival Pathways as Therapeutic Approaches against Primary Effusion Lymphomas: Past, Present, and Future

<div>Dose-response cytotoxic assay of BC3 and BCBL1 PEL cells treated with PES (HSP70 inhibitor) (Calbiochem) and Benzisoxazole (BENZ) (HSP90 inhibitor) (Calbiochem), at the indicated doses. Trypan blue exclusion assays were performed after 24 hours of treatment and mean ± SD of three independent experiments is reported.</div>

BioMed Research International

fig4

Figure 4

Figure 4: Targeting of Prosurvival Pathways as Therapeutic Approaches against Primary Effusion Lymphomas: Past, Present, and Future 